Eli Lilly and Company (LLY), Thursday announced topline results from SURPASS-CVOT, evaluating the efficacy and safety of Mounjaro compared with Trulicity in adults with type 2 diabetes and established atherosclerotic cardiovascular disease.
The randomized, double-blind, parallel group Phase 3 trial showed that Mounjaro achieved the primary objective by demonstrating a non-inferior rate of major adverse cardiovascular events.
Additionally, Mounjaro showed improvements on key measures of A1C, weight, renal function and all-cause mortality.
Kenneth Custer, executive vice president and president, Lilly Cardiometabolic Health, commented, "These findings strengthen the case for Mounjaro as a potential front-line treatment for people with type 2 diabetes and cardiovascular disease."
The company plans to submit these data to global regulatory authorities by the end of 2025.
In the pre-market hours, LLY is trading at $750.86, down 1.48 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Health News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.